Sofinnova Investments and General Catalyst led a $155m Series B round in ArriVent Biopharma.

Sofinnova Investments and General Catalyst led a $155m Series B round in ArriVent Biopharma, a company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, with participation from Catalio Capital Management, HBM Healthcare Investments, Shanghai Healthcare Capital, Sequoia China, AIHC Capital, Terra Magnum Capital Partners, Unicorn Capital Partners, Lilly Asia Ventures, OrbiMed, Octagon Capital Advisors, Sirona Capital, and Boyu Capital. “We are pleased to have attracted capital and support from leading new and existing investors, and to welcome two new distinguished board members, who recognize the urgency and value of globalizing innovative medicines for patients who have limited treatment options. With this Series B financing, we have now raised more than $300m to date, resulting in a strong financial position to further advance and broaden our global development plans for furmonertinib, as well as support our growing pipeline of best and first-in-class oncology therapeutics," Bing Yao, ArriVent Chairman, Co-founder and Chief Executive Officer.